


Abstract

The present application relates to a compound represented by Formula I, its isomer, isotope-labeled compound, or pharmaceutically acceptable salt thereof, and the use thereof as an ATR kinase inhibitor and for treating a cancer, wherein each group is as defined herein.



Formula I

[No figure]